BPD Cell & Gene Therapy Virtual Symposium and Vendor Show
Sponsored by Aldevron
Cell- and gene-based therapies are being developed rapidly by numerous companies, including those operating in North Carolina. However, these companies face ongoing challenges including adequate product characterization, new safety risks, and the need for reliable and cost-effective manufacturing solutions. Currently, standardization of equipment, methods, and integrated automation are lagging for cell- and gene-based therapy product manufacturing. BPD is hosting a day-long virtual symposium to discuss these challenges and give attendees the opportunity to learn and network.
Sponsored by Aldevron, BPD's free symposium on will include speakers from Pfizer, Biogen, Cellectis, KBI, and Precision Biosciences, Inc. Breaks between speakers will allow participants to visit virtual vendors, network, and participate in follow on discussions focused on topics presented by our speakers.
Virtual Exhibitors will include Aldevron, Akron Biotech, Beckman Coulter, Eppendorf Bioprocess, IPS-Integrated Project Services, Lighthouse Worldwide Solutions, MaxCyte, Millipore Sigma,LLC, Pall Corp, Repligen, and Watson Marlow.
Agenda
9:00-9:05 a.m.: Welcome and Introductions
9:05-9:40 a.m.
“Advanced allogeneic gene-edited cell therapy manufacturing - An introduction to Cellectis, UCART therapies and our Raleigh facility.”
Tony Thatcher - US Head, Manufacturing Science and Technology at Cellectis.
9:40-10:15 a.m.
“Allogeneic CAR-T: Positioning the Platform.”
Brent Rice, Ph.D. - Director, MS&T at Precision BioSciences, Inc.
10:15-10:45 a.m.: Breakout rooms - Vendor Show Part 1, Continued Discussion, Networking
10:45-11:20 a.m.
“Revolutionary gamma/delta T-cell manufacturing: why we need you and why you should come work with us.”
Tim Gallagher - Chief Business Officer at PhosphoGam
11:25 a.m.-12:00 p.m.
“From NC Biotech Seed Funding to Completion of World’s First Controlled Clinical Trial for a CRISPR-Enhanced Bacteriophage Therapy: Insights into Locus Biosciences’ Platform & Agile Drug Development Philosophy”
Nick Conley, Ph.D. - Sr. Director, Manufacturing Sciences & Technology, CMC at Locus Biosciences
12:00-1:00 p.m.: Breakout rooms - Vendor Show Part 2, Continued Discussion, Networking
1:00-2:00 p.m.: Launch Bio's Gene Therapy Panel - “Gene Therapy Thrives: Five Years of Growth in NC” including Astellas Gene Therapies, Novartis Gene Therapies, Beam Therapeutics, and Sarepta (separate registration link is below)
2:15-2:50 p.m.
“Development of AAV Bioprocesses for Improved Productivity”
Jeffrey Pavlicek, Ph.D. - Senior Principal Scientist, Gene Therapy Process Development at Pfizer
2:55-3:30 p.m.
“Gene Therapy Starts with Critical Starting Materials”
Greg Stromberg - Director, Global Manufacturing Sciences at Biogen
3:30-4:15 p.m.: Breakout rooms - Vendor Show Part 3, Continued Discussion, Networking
4:15-5:00 p.m.
“KBI: Your CDMO partner for cell therapy manufacturing”
Lauren Collison, Ph.D. - SVP of Operations, Site Head, Cell Therapy at KBI
More Information
Time will be available at 1 p.m. to allow participants to attend Launch Bio's "Gene Therapy Thrives: Five Years of Growth in NC" free virtual panel without missing any BPD content. Registration for these two events are separate.
What makes North Carolina great for gene therapy? Experts from Sarepta, Novartis Gene Therapy, Beam Therapeutics, Astellas Gene Therapies, and North Carolina Biotechnology Center will discuss the emergence of the state’s gene therapy ecosystem and share their predictions for the future of the industry. Register for Launch Bio’s Webinar here.
Virtual Event